ALB and cancer: The hypersensitive C‐reactive protein‐albumin ratio (CAR) is calculated from hypersensitive C‐reactive protein (Hs‐CRP), and albumin (ALB) has been reported as a new and sensitive marker and is associated with poor outcomes in patients with tumors or cancer, critically ill patients, and patients with various brain diseases, such as spontaneous intracerebral hemorrhage (Bender et al., 2020; Park et al., 2018).